NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results

NeoGenomics (NASDAQ:NEO) issued its quarterly earnings data on Tuesday. The medical research company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02, FiscalAI reports. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The company had revenue of $190.17 million for the quarter, compared to analyst estimates of $188.25 million. During the same period in the prior year, the firm earned $0.04 earnings per share. The company’s revenue was up 10.6% on a year-over-year basis.

Here are the key takeaways from NeoGenomics’ conference call:

• Strong financial momentum: Record Q4 revenue of $190M (+11% YoY) and FY revenue $727M (+10%), with clinical revenue up 16% in Q4, the 10th consecutive quarter of positive adjusted EBITDA ($13.4M Q4; $43.4M FY) and positive operating cash flow, signaling improving profitability and cash generation.
• RaDaR ST launch and reimbursement progress: MolDX coverage secured for HPV‑negative head & neck and a breast subset, a full clinical launch is planned by month‑end, two additional MolDX submissions are pending, and the company expects modest mid‑single‑million revenue in 2026 with acceleration in 2027 while expanding sales coverage (initial ENT focus and >25 OSS planned by Q3).
• PanTracer and NGS momentum but reimbursement timing matters: PanTracer Tissue volumes have shown rapid growth and PanTracer Pro was launched; PanTracer LBx (liquid) is submitted to MolDX and could add modest revenue in H2 2026 if approved, while NGS revenue grew 23% in Q4 and now represents about one‑third of clinical revenue.
• Strategic shift to higher‑value testing and 2026 outlook: Management is intentionally exiting low‑value, high‑volume contracts to prioritize higher‑AUP NGS and MRD testing; 2026 guidance is $793M–$801M revenue and $55M–$57M adjusted EBITDA, with a stated goal of becoming free‑cash‑flow positive this year.
• Operational investments and multi‑year efficiency plan: The PathLine acquisition expands Northeast presence and is expected to be accretive in 2026, while a companywide LIMS rollout, automation and analytics are targeted to drive margin improvements (more meaningfully in 2027–2028), but near‑term investments could temper immediate upside.

NeoGenomics Trading Down 10.3%

Shares of NeoGenomics stock opened at $10.26 on Thursday. The stock has a market capitalization of $1.33 billion, a P/E ratio of -12.21 and a beta of 1.58. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $13.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 4.26. The stock’s 50-day simple moving average is $12.13 and its 200 day simple moving average is $10.11.

Insider Activity at NeoGenomics

In other news, COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at $1,520,387.50. This trade represents a 15.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total value of $250,992.00. Following the completion of the sale, the executive vice president owned 31,083 shares in the company, valued at $372,996. This trade represents a 40.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On NeoGenomics

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its holdings in shares of NeoGenomics by 51.2% during the first quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock worth $532,000 after purchasing an additional 18,966 shares during the period. AQR Capital Management LLC bought a new position in NeoGenomics during the 1st quarter valued at approximately $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in NeoGenomics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock worth $719,000 after buying an additional 3,254 shares during the period. Intech Investment Management LLC grew its position in shares of NeoGenomics by 19.7% in the 1st quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock worth $1,441,000 after buying an additional 24,965 shares during the last quarter. Finally, Creative Planning increased its stake in shares of NeoGenomics by 20.4% during the second quarter. Creative Planning now owns 16,735 shares of the medical research company’s stock valued at $122,000 after buying an additional 2,840 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NEO shares. Benchmark reissued a “hold” rating on shares of NeoGenomics in a research note on Wednesday. Needham & Company LLC upped their target price on NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Leerink Partners set a $14.00 price target on shares of NeoGenomics in a research note on Tuesday, October 28th. Finally, Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, NeoGenomics has a consensus rating of “Hold” and an average price target of $11.57.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.